Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results
Authors:
- Peter K. KaiserPKPeter K. Kaiser
- David M. BrownDBDavid M. Brown
- Kang ZhangKZKang Zhang
- Henry L. HudsonHHHenry L. Hudson
- Frank G. HolzFHFrank G. Holz
- Howard ShapiroHSHoward Shapiro
- Susan SchneiderSSSusan Schneider
- Nisha R. AcharyaNANisha R. Acharya
Top Cited Papers
- 1 December 2007
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 144 (6) , 850-857.e4
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular DegenerationOphthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASERetina, 2005
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003
- Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Are Present in Epiretinal and Choroidal Neovascular MembranesAmerican Journal of Ophthalmology, 1996